Bluebird - International Biopharmaceutical Industry

news

Bluebird’s CFO resigns as cash woes raise doubts about its future

Dive Brief: Bluebird bio's chief financial officer Gina Consylman will resign amid growing concerns the company needs to raise additional money to survive more tha...

14 March 2022 news Bluebird | financial

Continue Reading →

news

Bluebird faces longer wait for FDA verdict on experimental gene therapies

Dive Brief: Bluebird bio will need to wait longer for a decision from the Food and Drug Administration on approval of two gene therapies it submitted last year, an...

20 January 2022 news approval | blood

Continue Reading →

news

Aftershocks for Lilly, CRISPR versus CRISPR and Bluebird’s crucial year

The biggest industry news of the week came not from the J.P. Morgan Healthcare Conference or any associated announcements, but from Washington, D.C, where the Centers...

14 January 2022 news Alzheimer | blood

Continue Reading →

news

Bluebird, after delays, gets speedy FDA review for beta thalassemia gene therapy

The FDA's acceptance of Bluebird's application, which comes two months after the company submitted it to the agency, marks the final stretch of a long road for the tr...

26 November 2021 news Bluebird | FDA

Continue Reading →

news

FDA clears Rocket to resume testing gene therapy for a rare heart disease

Rocket's program has been in limbo since early May, when the company surprised investors and analysts with news of the trial's stoppage. That announcement stalled wh...

20 August 2021 news Bluebird | FDA

Continue Reading →